Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report

[1] Kyle RA(1995)Primary systemic amyloidosis: clinical and laboratory features in 474 cases Semin Hematol 32 45-59

[2] Gertz MA(2011)Light chain (AL) amyloidosis: update on diagnosis and management J Hematol Oncol 4 47-1590

[3] Rosenzweig M(2016)Liver transplantation is a potential treatment option for systemic light chain amyloidosis patients with dominant hepatic involvement: a case report and analytical review of the literature Intern Med 55 1585-4390

[4] Landau H(2012)Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival Blood. 119 4387-728

[5] Ueno A(2016)The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy Clin Adv Hematol Oncol 14 719-1768

[6] Katoh N(2011)Renal transplantation in light chain amyloidosis: coming out of the cupboard Nephrol Dial Transplant 26 1766-357

[7] Aramaki O(1962)Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients Am J Med 33 349-298

[8] Makuuchi M(2003)Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients Medicine (Baltimore) 82 291-262

[9] Ikeda S(2008)Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis Eur J Cardiothorac Surg 33 257-2654

[10] Venner CP(2016)Systemic amyloidosis Lancet. 387 2641-38

[1] Kyle RA(1995)Primary systemic amyloidosis: clinical and laboratory features in 474 cases Semin Hematol 32 45-59

[2] Gertz MA(2011)Light chain (AL) amyloidosis: update on diagnosis and management J Hematol Oncol 4 47-1590

[3] Rosenzweig M(2016)Liver transplantation is a potential treatment option for systemic light chain amyloidosis patients with dominant hepatic involvement: a case report and analytical review of the literature Intern Med 55 1585-4390

[4] Landau H(2012)Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival Blood. 119 4387-728

[5] Ueno A(2016)The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy Clin Adv Hematol Oncol 14 719-1768

[6] Katoh N(2011)Renal transplantation in light chain amyloidosis: coming out of the cupboard Nephrol Dial Transplant 26 1766-357

[7] Aramaki O(1962)Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients Am J Med 33 349-298

[8] Makuuchi M(2003)Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients Medicine (Baltimore) 82 291-262

[9] Ikeda S(2008)Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis Eur J Cardiothorac Surg 33 257-2654

[10] Venner CP(2016)Systemic amyloidosis Lancet. 387 2641-38